Press

news-magnifyglass.png

Crown Bioscience San Diego Center of Excellence Announces New General Manager

March 16, 2017

(Santa Clara, Calif., March 16, 2016) — Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, announces the promotion of Dr. Jayant Thatte to General Manager, heading up the company’s center of excellence in San Diego.

Dr. Thatte is an immunologist with 20 years of research experience in both academia and industry, focusing on cancer, autoimmunity, inflammation and pain. As Director of R&D and Associate Director of Operations at Molecular Response, he led the pharmacology team for numerous client projects that significantly increased revenue growth for the company, which ultimately resulted in the acquisition of PDX business by Crown Bioscience.

Michael Prosser, Vice President of CrownBio’s European and North American operations commented: “Dr. Thatte brings established leadership and decades of research experience to the General Manager role. As COO of CrownBio San Diego, Jayant has played a central role in the site’s recent growth and success, leading the teams to deliver PDX, syngeneic, cell-line xenograft, and humanized PDX/xenograft platforms, supporting both immuno-oncology and targeted therapy programs for our clients.”

Prosser further thanked Dr. Tommy Broudy, who came to CrownBio with the acquisition of Molecular Response, for his contribution. “Tommy has been a valuable colleague during both the acquisition and subsequent integration of Molecular Response. Since joining CrownBio our San Diego site has evolved and grown into a multi-platform center of excellence, and we appreciate Tommy’s key contribution in this accomplishment.”

Dr. Jean Pierre Wery, CEO of CrownBio also stated “CrownBio invests in our teams’ leadership development and succession plans so that dedicated individuals, such as Thatte, are ready to step up and into new roles when needed and to support sustained growth.”

About Crown Bioscience Inc.

Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.

Media Enquiries:
Jody Barbeau
Crown Bioscience Inc. marketing@crownbio.com